Recent research indicates a correlation between over the counter heartburn medications and kidney disease. A study released in the January JAMA Internal Medicine journal reveled that some patients with long term use of popular heartburn, indigestion, and acid reflux medications had an increased risk of kidney disease and kidney failure. The study, involving more than 250,000 people, revealed that people who use proton-pump inhibitors (“PPIs”) had a 20 percent to 50 percent increased risk of developing kidney disease or kidney failure compared to nonusers.
PPIs, like Prevacid, Prilosec, and Nexium, are over the counter medicines used to treat heartburn, acid reflux, and ulcers. These medications lower the amount of acid produced by the stomach. Dr. Morgan Grams, an assistant professor of epidemiology at Johns Hopkins University, and leader of the January study, claims the results of the study do not necessarily prove a causal connection between PPI’s and chronic kidney disease. Instead, Grams asserts that increased dosages of PPI’s may lead to an increased risk of chronic kidney disease. This is particularly concerning given that Benjamin Lazarus, from the Department of Epidemiology at Johns Hopkins University, indicates more than 15 million Americans used PPIs in 2013.
A second study released in April in the Journal of the American Society of Nephrology corroborated the results of the January study, including the finding that long-term use of PPIs might lead to an increased risk of kidney disease. In the April study, researchers examined database information from the Department of Veterans Affairs and identified 170,000 PPI users. Researchers followed-up with the PPI cohort after five years and found that 15 percent were diagnosed with chronic kidney disease.
In a recent NPR article, John Clarke, a gastroenterologist at Johns Hopkins Hospital, stated in his opinion the root of the PPI problem could be that PPIs decrease the production of stomach acid. According to Clarke, stomach acid, in part, acts as a barrier against various pathogens that are ingested. As a result, when there is less stomach acid, people can be more susceptible to nutritional deficiencies and infections.
Other physicians, like Dr. Paul Buckley, surgical director at the Scott & White Clinic, claim part of the problem may be misuse of PPIs. In an article published in WebMd, Dr. Buckley argued PPIs are inappropriate to use for occasional bouts of heartburn. Instead, in Dr. Buckley’s opinion, PPIs should be reserved for individuals with gastroesophageal reflux disease (GERD). Adam Schoenfeld, a resident at the University of California, San Francisco, recommends that individuals first be told to try adjusting their diet and reduce their alcohol consumption. In other words, PPIs should not be taken as a quick fix.
In addition to kidney disease, increased use of PPI’s has been linked to other health conditions. For example, according to the U.S. Food and Drug Administration, PPI’s may be linked to nutrient deficiencies and bone-density loss. The FDA warns that individuals who use PPIs for a year or more may have an increased risk of hip, wrist, and spine fractures.
These studies indicate that, like other medications, despite being sold over the counter, PPIs have their own health risks. As such, individuals should consult their physician before going on to a PPI.
David Rapoport is the founding and managing partner of Rapoport Law Offices. In his over 31 years as a full time trial attorney, he has won numerous multi-million dollar jury verdicts and settlements in personal injury and wrongful death cases. Mr. Rapoport is a member of the invitation only American Board of Trial Advocates (ABOTA), an association of premier trial attorneys who are dedicated to preserving the right to trial by jury. ABOTA's general mission is "to foster improvement in the ethical and technical standards of practice in the field of advocacy to the end that individual litigants may receive more effective representation and the general public be benefited by more efficient administration of justice consistent with time-tested and traditional principles of litigation." For over 20 years Martindale-Hubbell, through its Peer Review RatingsTM program, has consistently ranked David Rapoport as AV® PreeminentTM, its highest professional rating. This is a testament to Mr. Rapoport's abilities as an attorney and commitment to maintaining the highest ethical standards. Mr. Rapoport has also been selected by Thompson Reuters, another prominent legal publisher, as an Illinois “Super Lawyer” every year since the inception of the Super Lawyer program. Super Lawyer designation is limited to the top 5 percent of lawyers in a state in any given year. Since 1990, David Rapoport has been board certified* in Civil Trial Advocacy by the National Board of Trial Advocacy ("NBTA"), the oldest and largest not-for-profit American Bar Association accredited trial attorney certification program. Attorneys with NBTA certification have proven ability in their field through specialized written examinations and meeting rigorous criteria for trial experience and ethical ratings. Mr. Rapoport has proven his currency and substantial trial experience through NBTA recertification in 1995, 2000, 2005 and 2010. David Rapoport has served as a leader of the movement to encourage board certification for trial lawyers for more than twenty years. Currently he is the President of the National Board of Trial Advocacy and its parent organization the National Board of Legal Specialty Certification. He recently explained: "In this era of Wild West style minimally regulated lawyer advertising, it has never been more important for the public to have easy and reliable means of identifying members of the small fraction of practicing attorneys who truly have substantial experience trying cases. Board certification programs help consumers of legal services make more informed choices. Too many lawyers are out there claiming to have substantial trial experience when in truth they have never tried a case. Board certified trial lawyers have proven their substantial trial experience in ways the public can trust." Mr. Rapoport is a member of the President's Club and Leader's Forum of the American Association for Justice and the state trial lawyer associations in Illinois, Wisconsin and Kentucky. He is also a member of the Economic Club of Chicago. * Board certification is not required to practice law in Illinois and the Illinois Supreme Court does not recognize specialties in the practice of law.